FrancophonIA/ELRC3.0 huggingface dataset:
English: [EMA/MB/276960/2010; EMA/319831/2010] The Management Board noted the Agency's report to the European Commission providing the Agency's views on the experience with the Fee Regulation.
Estonian: [EMA/MB/276960/2010; EMA/319831/2010] Haldusnõukogu võttis teadmiseks ravimiameti aruande Euroopa Komisjonile, milles on esitatud ravimiameti seisukohad tema kogemustest lõivude määrusega.
English: Ombudsman and access to EMA documents
Estonian: Ombudsmani otsused Euroopa Ravimiameti dokumentide kättesaadavuse kohta
English: The Agency works to address the issues and will adopt the same approach to data released reactively and proactively.
Estonian: Ravimiamet püüab probleemi lahendada ja võtta kasutusele sama lähenemise nii taotluste alusel kui ka ennetavalt avalikustatava teabe korral.
English: • The progress on the HMA strategy paper.
Estonian: • edusammud seoses ravimiametite juhtide strateegiadokumendiga.
English: [EMA/MB/372194/2010, EMA/MB/400828/2010] The Management Board noted the decision of the European Commission to re-open the vacancy announcement following advice of the European Commission legal service with regard to a wider publication of the vacancy.
Estonian: [EMA/MB/372194/2010, EMA/MB/400828/2010] Haldusnõukogu võttis teadmiseks Euroopa Komisjoni otsuse avaldada uuesti teade ametikoha täitmise kohta pärast seda, kui Euroopa Komisjoni õigustalitus oli soovitanud vaba ametikoha täitmist laiemalt reklaamida.
English: Chair: Pat O'Mahony
Estonian: Juhataja: Pat O'Mahony
English: Report from the Heads of Medicines Agencies
Estonian: Ravimiametite juhtide aruanne
English: The number of data fields to be removed varies in different cases.
Estonian: Olenevalt juhtumist on avalikustamisel välja jäetavate väljade arv erinev.
English: New appointments
Estonian: Ametissenimetamised
English: Minutes of the 67th meeting of the Management Board
Estonian: Haldusnõukogu 67. koosoleku protokoll
English: [EMA/MB/354158/2010] The Management Board endorsed the appointment of an ad interim accounting officer until the return to office of the accounting officer.
Estonian: [EMA/MB/354158/2010] Haldusnõukogu kinnitas peaarvepidaja kohusetäitja ametissenimetamise kuni peaarvepidaja töölenaasmiseni.
English: Minutes from the 66th meeting, held on 17-18 March 2010
Estonian: 17.-18. märtsil 2010 toimunud 66. koosoleku protokoll
English: Representative of doctors' organisations
Estonian: Arstiühingute esindaja
English: The Board recognised that the arrangements on handing of conflicts of interest differ in different Member States and this needs to be reflected in the memorandum.
Estonian: Haldusnõukogu märkis, et vastastikuse mõistmise memorandumit on vaja sellepärast, et liikmesriigid käsitlevad huvide konflikte erinevalt.
English: Human medicinal products
Estonian: Inimravimid
English: [EMA/MB/298741/2010] The Management Board discussed two ongoing consultation procedures: one for the CVMP and one for the CHMP.
Estonian: [EMA/MB/298741/2010] Haldusnõukogu arutas kaht käimasolevat konsultatsioonimenetust seoses inimravimite komitee ja veterinaarravimite komitee uute liikmetega.
English: • Agenda point 10_Advertisement of the vacancy notice for the recruitment of the Executive Director for the EMA.
Estonian: • Päevakorra 10. punkt: Teade Euroopa Ravimiameti tegevdirektori ametikoha täitmise kohta.
English: [EMA/MB/282448/2010] The Management Board heard the report on arbitration and referral activities of the CVMP.
Estonian: [EMA/MB/282448/2010] Haldusnõukogu kuulas ära aruande veterinaarravimite komiteele tehtud ühenduse esildistega seotud vahekohtumenetluste kohta.
English: Representative of veterinarians' organisations
Estonian: Veterinaarühingute esindaja Henk Vaarkamp Vaatlejad
English: Update on future accommodation of the Agency
Estonian: Info ravimiameti tulevaste ruumide kohta
English: Ref. EMEA/652773/2009 EMEA/H/C/1040
Estonian: London, 22. oktoober 2009 Viide: EMEA/769808/2009 EMEA/H/C/1040
English: What is Zunrisa?
Estonian: Mis on Zunrisa?
English: It was expected to be available as tablets (50 and 150 mg).
Estonian: Ravimit kavatseti turustada tablettidena (50 ja 150 mg).
English: Following the CHMP's opinion, it usually takes around two months for the European Commission to issue a decision on this opinion.
Estonian: Pärast komitee arvamuse esitamist kulub Euroopa Komisjonil arvamuse kohta otsuse tegemiseks ligikaudu kaks kuud.
English: However that trial was being stopped.
Estonian: See uuring oli siiski katkestamisel.
English: The application was at day 180 when the company withdrew.
Estonian: Taotluse menetlemine oli kestnud 180 päeva, kui ettevõte selle tagasi võttis.
English: Zunrisa is a medicine that contains the active substance casopitant.
Estonian: Zunrisa on ravim, mis sisaldab toimeainena kasopitanti.
English: When substance P attaches to these receptors, it can cause nausea and vomiting.
Estonian: Kui P-aine seondub nende retseptoritega, võib see põhjustada iiveldust ja oksendamist.
English: The active substance in Zunrisa, casopitant, is a ‘neurokinin 1 (NK1) receptor antagonist'.
Estonian: Zunrisa toimeaine kasopitant on neurokiniin-1 (NK1) retseptori antagonist.
English: The Committee also asked the company to reconsider the target population for patients having surgery to ensure it adequately reflected the kind of patients who were involved in the studies.
Estonian: Samuti palus komitee ettevõttel sihtpopulatsioon opereeritavate patsientide seisukohalt üle vaadata ning veenduda, et uuringutesse kaasatud patsiendid peegeldavad seda asjakohaselt.
English: If you are a patient in this trial and need more information about your treatment, contact the doctor who is treating you.
Estonian: Kui osalete selles kliinilises uuringus ning vajate ravi kohta lisateavet, pöörduge oma raviarsti poole.
English: Questions and answers on the withdrawal of the marketing authorisation application for Zunrisa casopitant
Estonian: Teave müügiloa taotluse tagasivõtmise kohta Zunrisa kasopitant
English: What are the consequences of the withdrawal for patients in clinical trials or compassionate use programmes using Zunrisa?
Estonian: Millised on taotluse tagasivõtmise tagajärjed Zunrisa kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
English: It blocks a chemical in the body called substance P from attaching to the NK1 receptors.
Estonian: See takistab organismi kemikaali, P-aine seondumist NK1-retseptoritega.
English: Once the company has supplied responses to the questions, the CHMP reviews them and may, before giving an opinion, ask any remaining questions at day 180.
Estonian: Kui ettevõte on küsimustele vastanud, vaatab inimravimite komitee vastused läbi ja võib enne arvamuse koostamist esitada 180. päeval veel küsimusi.
English: After the CHMP had assessed the responses from the company to a list of questions, there were still some unresolved issues.
Estonian: Inimravimite komitee oli ettevõttele esitatud küsimuste vastused läbi vaadanud, kuid mõni küsimus oli veel lahendamata.
English: The patients were given a combination of Zunrisa with two other medicines (dexamethasone and ondansetron) or the combination without Zunrisa.
Estonian: Patsientidele manustati Zunrisat koos kahe teise ravimiga (deksametasoon ja ondansetroon) või ravimite kombinatsiooni ilma Zunrisata.
English: On 25 September 2009, Glaxo Group Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Zunrisa, for the prevention of nausea and vomiting in patients undergoing surgery or receiving chemotherapy.
Estonian: 25. septembril 2009 teatas Glaxo Group Ltd ametlikult inimravimite komiteele oma soovist võtta tagasi opereeritavatel või kemoteraapiat saavatel patsientidel iivelduse ja oksendamise ennetamiseks mõeldud ravimi Zunrisa müügiloa taotlus.
English: The main measure of effectiveness was the number of patients who did not vomit or needed to be given rescue medication for vomiting in the first five days following the start of a cycle of chemotherapy.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kes ei oksendanud ega vajanud oksendamisvastast ravimit esimesel viiel päeval pärast kemoteraapia kuuri alustamist.
English: How is Zunrisa expected to work?
Estonian: Milline on Zunrisa eeldatav toime?
English: The company presented data from large studies in cancer patients receiving chemotherapy.
Estonian: Ettevõte esitas andmed kemoteraapiat saavaid vähipatsiente hõlmavate ulatuslike uuringute kohta.
English: The main measure of effectiveness for the study was the number of patients who did not vomit or needed to be given any rescue medication in the first 24 hours after surgery.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kes ei oksendanud ega vajanud oksendamisvastast ravimit esimese 24 tunni jooksul pärast operatsiooni.
English: The company also presented data from studies in patients at a high risk of having nausea and vomiting after surgery.
Estonian: Samuti esitas ettevõte andmed uuringutest, milles osalesid patsiendid, kellel oli operatsioonijärgse iivelduse ja oksendamise suur risk.
English: After looking at the results of the main studies, the CHMP noted that, while the studies showed that Zunrisa was effective in some cancer patients receiving chemotherapy, its use in patients receiving chemotherapy treatments that are moderate triggers of nausea and vomiting was not fully supported by the results.
Estonian: Pärast põhiuuringute tulemustega tutvumist märkis inimravimite komitee, et ehkki uuringute tulemuste kohaselt oli Zunrisa mõne kemoteraapiat saava vähipatsiendi puhul tõhus, ei toeta tulemused täielikult ravimi kasutamist patsientidel, kes saavad mõõdukat iiveldust ja oksendamist põhjustavat kemoteraapiat.
English: The patients received Zunrisa with ondansetron or ondansetron alone.
Estonian: Patsientidele manustati Zunrisat koos ondansetrooniga või ainult ondansetrooni.
English: By blocking the receptors, casopitant was expected to prevent nausea and vomiting which often happens during chemotherapy or as a complication of surgery.
Estonian: Retseptorite blokeerimise abil ennetab kasopitant eeldatavalt iiveldust ja oksendamist, mis kaasneb sageli kemoteraapiaga või tekib pärast operatsiooni.
English: The company informed the CHMP that at the time of the withdrawal one clinical trial with Zunrisa was ongoing.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmise ajal oli käimas üks Zunrisa kliiniline uuring.
English: Zunrisa was expected to be used in combination with other medicines to prevent nausea and vomiting in patients receiving chemotherapy treatments (medicines to treat cancer) that are moderate or strong triggers of nausea and vomiting.
Estonian: Zunrisat kavatseti kasutada koos teiste ravimitega iivelduse ja oksendamise ennetamiseks patsientidel, kes saavad kemoteraapiat (vähiravimeid), mis kutsub esile mõõduka või tugeva iivelduse ja oksendamise.
English: The effects of Zunrisa were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Zunrisa toimet muude katsetega.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Zunrisa could not have been approved for use with other medicines in the prevention of nausea and vomiting in patients receiving chemotherapy or in those undergoing surgery.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi inimravimite komitee taotluse tagasivõtmise ajal põhjuseid ettevaatlikkuseks ning oli esialgu seisukohal, et Zunrisa kasutamist koos teiste ravimitega iivelduse ja oksendamise ennetamiseks patsientidel, kes saavad kemoteraapiat või keda opereeritakse, ei ole võimalik heaks kiita.
English: What was Zunrisa expected to be used for?
Estonian: Milleks kavatseti Zunrisat kasutada?
English: Zunrisa was also expected to be used with other medicines to prevent nausea and vomiting in patients undergoing surgery.
Estonian: Zunrisat kavatseti kasutada koos teiste ravimitega ka opereeritavatel patsientidel iivelduse ja oksendamise ennetamiseks.
English: The referral procedure started on 19 September 2005.
Estonian: Esildismenetlus algas 19. septembril 2005.
English: Page 2/2 ©EMEA 2007
Estonian: Lehekülg 2/2 ©EMEA 2007
English: The final opinion was converted into a Decision by the European Commission on 4 July 2006.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 4. juulil 2006.
English: The Member States competent authorities will continue to keep the product under regular review.
Estonian: Liikmesriikide pädevad asutused jätkavad kõnealuse ravimi regulaarset järelevalvet.
English: International Non-Proprietary Name (INN): salmeterol / fluticasone
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): salmeterool / flutikasoon
English: VIANI DISKUS and associated names (See Annex I)
Estonian: VIANI DISKUS ja sarnaseid nimetusi (vt I lisa)
English: In the MRP Sweden is the Reference Member State (RMS) and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and the United Kingdom are Concerned Member States (CMS).
Estonian: Vastastikuse tunnustamise menetluses on viiteliikmesriigiks Rootsi ning asjaomasteks liikmesriikideks Austria, Belgia, Soome, Prantsusmaa, Saksamaa, Itaalia, Iirimaa, Luksemburg, Portugal, Hispaania ning Ühendkuningriik.
English: The Rapporteur and Co-Rapporteur appointed were Dr D Lyons and Dr G Calvo Rojas, respectively.
Estonian: Ettekandjaks ja kaasettekandjaks määrati vastavalt dr D. Lyons ja dr G. Calvo Rojas.
English: Supplementary information was provided by the Marketing Authorisation Holders on 3 February 2006 and written explanations were given on 30 March 2006.
Estonian: Müügiloa hoidjad esitasid täiendava teabe 3. veebruaril 2006 ning kirjalikud selgitused esitati 30. märtsil 2006.
English: In several EU Member States Viani Diskus and associated names are approved through the Mutual Recognition Procedure (MRP).
Estonian: Mitmes ELi liikmesriigis on Viani Diskus ja sarnased nimetused vastastikuse tunnustamise menetluse abil heaks kiidetud.
English: *Note: the information given in this document and Annexes reflect only the CHMP Opinion dated 27 April 2006.
Estonian: * Märkus: käesolevas dokumendis ja selle lisades esitatud teave kajastab ainult inimtervishoius kasutavate ravimite komitee 27. aprilli 2006. aasta arvamust.
English: 4 July 2006 EMEA/306421/2006
Estonian: 4. juuli 2006 EMEA/306421/2006
English: Viani Diskus and associated names (see Annex I) contain salmeterol and fluticasone propionate, a fixed dose combination of the long acting β-agonist salmeterol and the inhaled corticosteroid fluticasone propionate and is indicated for the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.
Estonian: Viani Diskus ja sarnased nimetused (vt I lisa) sisaldavad salmeterooli ja flutikasoonpropionaati - pika toimeajaga beetaagonisti salmeterooli ja sissehingatava kortikosteroidi flutikasoonpropionaadi fikseeritud dooside kombinatsiooni, mis on näidustatud astma tavaraviks, kui liittoote (pika toimeajaga beeta2-agonist ja sissehingatav kortikosteroid) kasutamine on asjakohane: patsientidel, kes ei allu hästi ravile sissehingatavate kortikosteroididega ja lühikese toimeajaga vajadusel sissehingatava beeta2agonistiga, või patsientidel, kes alluvad juba tõestatult hästi ravile sissehingatava kortikosteroidi ja pika toimeajaga beeta2-agonistiga manustatuna koos.
English: On 12 August 2005 the Marketing Authorisation Holders presented to the EMEA a referral under article 6(13) of Commission Regulation (EC) No 1084/2003.
Estonian: 12. augustil 2005 esitasid müügiloa hoidjad Euroopa Ravimiametile komisjoni määruse (EÜ) nr 1084/2003 artikli 6 lõike 13 alusel esildise.
English: Based on evaluation of the available data and the Rapporteur's assessment reports, the CHMP adopted an opinion on 27 April 2006 recommending the variation to the terms of the Marketing Authorisations with amendments to the Summary of Product Characteristics, Labelling and Package leaflet .
Estonian: Olemasolevate andmete hindamisele ja ettekandjate hindamisaruannetele tuginedes võttis inimtervishoius kasutatavate ravimite komitee 27. aprillil 2006 vastu arvamuse, milles soovitas muuta müügiloa tingimusi ning teha muudatused ravimiomaduste kokkuvõttes, märgistuses ja pakendi infolehes.
English: The Marketing Authorisation Holders submitted a type II variation subject to the MRP in July 2004 to extend the indication to include initial maintenance therapy with the fixed dose combination in patients with chronic persistent asthma.
Estonian: Müügiloa hoidjad esitasid 2004. aasta juulis taotluse II tüüpi teisendi kohta, millele kohaldataks vastastikuse tunnustamise menetlust, et laiendada näidustusi niiviisi, et need hõlmaksid ka kroonilise persistentse astmaga patsientide esmast säilitavat ravi fikseeritud annustega kombinatsiooniga.
English: On the basis of the grounds for referral, the point considered by the CHMP was whether it is appropriate to introduce initial maintenance therapy with the fixed dose combination of salmeterol and fluticasone propionate in all patients with chronic persistent asthma.
Estonian: Esildise esitamise põhjuste alusel kaalus inimtervishoius kasutatavate ravimite komitee küsimust, kas on lubatav hakata kasutama esmast säilitavat ravi salmeterooli ja flutikasoonpropionaadi fikseeritud annustega kombinatsiooniga kõigi kroonilise persistentse astmaga patsientide puhul.
English: The RMS and CMSs rejected the type II variation based on the grounds that the overall risk/benefit was unfavourable for the initial maintenance therapy indication.
Estonian: Viiteliikmesriik ja asjaomased liikmesriigid lükkasid II tüüpi teisendi taotluse tagasi, sest üldine riski ja kasulikkuse suhe esmase säilitava ravi näidustuse puhul oli ebasoodne.
English: PERSUANT TO ARTICLE 6(13) OF COMMISSSION REGULATION (EC) No 1084/2003 FOR
Estonian: INIMTERVISHOIUS KASUTATAVATE RAVIMITE KOMITEE TEABEKOKKUVÕTE ARVAMUSEST KOMISJONI MÄÄRUSE (EÜ) 1084/3003 ARTIKLI 6 LÕIKE 13 KOHASE ESILDISE KOHTA, MIS KÄSITLES RAVIMIT
English: The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II, together with the amended Summary of Product Characteristics, Labelling and Package Leaflet in the Annex III.
Estonian: Asjaomaste tootenimetuste loetelu on esitatud I lisas ja teaduslikud järeldused II lisas.
English: Nucala received a marketing authorisation valid throughout the EU on 2 December 2015.
Estonian: Nucala on saanud müügiloa, mis kehtib kogu ELis, 2. detsembril 2015.
English: What measures are being taken to ensure the safe and effective use of Nucala?
Estonian: Mis meetmed võetakse, et tagada Nucala ohutu ja efektiivne kasutamine?
English: Further information on Nucala can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/nucala.
Estonian: Lisateave Nucala kohta on ameti veebilehel: ema.europa.eu/en/medicines/human/EPAR/nucala.
English: Nucala (mepolizumab)
Estonian: Nucala (mepolisumaab)
English: The European Medicines Agency decided that Nucala's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Nucala kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: As for all medicines, data on the use of Nucala are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Nucala kasutamise kohta pidevat järelevalvet.
English: This helps to reduce inflammation, resulting in a reduction in asthma attacks and improvement of symptoms.
Estonian: See aitab vähendada põletikku, mille tulemusel astmahood vähenevad ja sümptomid paranevad.
English: Side effects reported with Nucala are carefully evaluated and any necessary action taken to protect patients.
Estonian: Nucala kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Other information about Nucala
Estonian: Muu teave Nucala kohta
English: In addition, a reduction in corticosteroid dose was considered clinically relevant, given the potential complications of long-term corticosteroid treatment.
Estonian: Peale selle peeti kliiniliselt oluliseks kortikosteroidiannuse vähendamise võimalust, arvestades pikaajalise kortikosteroidravi potentsiaalseid tüsistusi.
English: It is used with other medicines in patients whose asthma is severe and not well controlled with previous treatments.
Estonian: Seda kasutatakse koos teiste ravimitega patsientidel, kelle astma on raske ega allunud piisavalt varasemale ravile.
English: Why is Nucala authorised in the EU?
Estonian: Miks Nucala ELis heaks kiideti?
English: The Agency concluded that the data available indicate that Nucala acts in a similar way in adults and children and the results in adults therefore also apply to children with eosinophilic asthma.
Estonian: Amet järeldas, et kättesaadavate andmete kohaselt on Nucala toimemehhanism lastel ja täiskasvanutel sama ning seepärast kehtivad tulemused ka eosinofiilse astmaga laste kohta.
English: What is Nucala and what is it used for?
Estonian: Mis on Nucala ja milleks seda kasutatakse?
English: In children, eosinophilic asthma is rare and the data available are therefore limited.
Estonian: Lastel esineb eosinofiilset astmat harva ja kättesaadavad andmed on seetõttu piiratud.
English: The patient and carer can use Nucala prefilled pen or syringe themselves once they have been trained, whereas the vial is only for use by a healthcare professional.
Estonian: Patsient ja hooldaja tohivad kasutada Nucala eeltäidetud pensüstalt või süstalt ise, kui nad on saanud väljaõppe; viaali tohib kasutada üksnes tervishoiutöötaja.
English: For more information about using Nucala, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Nucala kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: The most common side effect with Nucala (which may affect more than 1 in 10 people) is headache.
Estonian: Nucala kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on peavalu.
English: The second study involved 576 adults and adolescents given Nucala every 4 weeks for 28 weeks.
Estonian: Teises uuringus osales 576 täiskasvanut ja noorukit, kellele manustati Nucalat 28 nädala jooksul iga 4 nädala järel.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nucala have been included in the summary of product characteristics and the package leaflet.
Estonian: Nucala ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The reduction in eosinophil levels in the blood achieved in children was also comparable with that seen with standard doses in adults.
Estonian: Eosinofiilide sisaldus laste veres vähenes võrreldavalt sellega, mida täheldati täiskasvanutel standardannustega.
English: The medicine is given by injection under the skin of the upper arm, thigh or abdomen (belly) once every 4 weeks.
Estonian: Ravimit manustatakse süstina õlavarre, reie või kõhupiirkonna naha alla üks kord iga 4 nädala järel.
English: What are the risks associated with Nucala?
Estonian: Mis riskid Nucalaga kaasnevad?
English: In adults the reduction seen in severe asthma attacks and consequent need for hospital treatment was considered important and outweighed the low risk of side effects.
Estonian: Raskete astmahoogude ja nendest tulenevat haiglaravi vajaduse vähenemist täiskasvanutel peeti oluliseks ning see kaalus üles kõrvalnähtude väikese riski.